摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二氯喹啉-3-甲酸乙酯 | 6315-94-2

中文名称
2,4-二氯喹啉-3-甲酸乙酯
中文别名
2,4-二氯喹啉-3-羧酸乙酯
英文名称
ethyl 2,4-dichloroquinoline-3-carboxylate
英文别名
2,4-dichloro-3-ethoxycarbonylqiunoline;2,4-dichloro-quinoline-3-carboxylic acid ethyl ester;2,4-Dichlor-chinolin-3-carbonsaeure-aethylester;2,4-Dichloro-quinoline-3-carboxylic Acid Ethylester
2,4-二氯喹啉-3-甲酸乙酯化学式
CAS
6315-94-2
化学式
C12H9Cl2NO2
mdl
MFCD00572654
分子量
270.115
InChiKey
ULBLITMQCMVRMY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933499090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:26e9d1c63a556286bcfa1b5fafd3d8d2
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,4-二氯喹啉-3-甲酸乙酯sodium ethanolatesodium acetate 、 sodium hydride 、 1-羟基苯并三唑1,8-二氮杂双环[5.4.0]十一碳-7-烯盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 、 sodium hydroxide 作用下, 以 四氢呋喃乙醇溶剂黄146N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 86.17h, 生成 2-[4-({[3-methoxy-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-4,5-dihydro-1H-pyrrolo[3,2-c]quinolin-2-yl]carbonyl}amino)piperidin-1-yl]-2-oxoethyl acetate
    参考文献:
    名称:
    Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors
    摘要:
    The Hedgehog (Hh) signaling pathway plays a significant role in the regulation of cell growth and differentiation during embryonic development. Since activation of the Hh signaling pathway is implicated in several types of human cancers, inhibitors of this pathway could be promising anticancer agents. Using high throughput screening, thieno[3,2-c] quinoline-4-one derivative 9a was identified as a compound of interest with potent in vitro activity but poor metabolic stability. Our efforts focused on enhancement of in vitro inhibitory activity and metabolic stability, including core ring conversion and side chain optimization. This led to the discovery of pyrrolo[3,2-c] quinoline-4-one derivative 12b, which has a structure distinct from previously reported Hh signaling inhibitors. Compound 12b suppressed stromal Gli1 mRNA expression in a murine model and demonstrated antitumor activity in a murine medulloblastoma allograft model. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2012.07.039
  • 作为产物:
    描述:
    2,4-二羟基喹啉-3-甲酸乙酯三乙胺三氯氧磷 作用下, 反应 2.0h, 以98%的产率得到2,4-二氯喹啉-3-甲酸乙酯
    参考文献:
    名称:
    4-azido-2-oxoquinoline-3-羧酸盐和4-azidocoumarin-3羧酸盐的闭环和重排反应† ‡
    摘要:
    通过相应的4-羟基衍生物1经由4-甲苯磺酸酯2或4-氯化合物4从相应的4-羟基衍生物1中获得4-叠氮基-2-氧代喹啉-3-羧酸盐和4-叠氮杂多古灵-3-羧酸盐6,将它们在热解后环化成3-烷氧基异恶唑[ 4,3- c ]喹啉-4(5 H)-或相应的香豆素8,而在稍高的温度下,发生3- O,4- O重排,得到4-烷氧基-异恶唑[4]。 ,3- c ]-喹啉-3-酮和相应的香豆素9.借助差示扫描量热法可以容易地获得必要的反应条件。
    DOI:
    10.1002/jhet.5570350322
点击查看最新优质反应信息

文献信息

  • New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them
    申请人:——
    公开号:US20030004150A1
    公开(公告)日:2003-01-02
    A compound of the formula 1 wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.
    其中取代基如规范中所定义的化合物的化学式,这些化合物在癌症治疗中很有用。
  • [EN] QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS<br/>[FR] DÉRIVÉS DE QUINOLÉINE, DE NAPHTALÈNE, DE QUINOLÉINE OU DE NAPHTALÈNE CONTRAINT AU NIVEAU CONFORMATION EN TANT QU'AGENTS ANTIMYCOBACTÉRIENS
    申请人:CHATTOPADHYAYA JYOTI
    公开号:WO2009091324A1
    公开(公告)日:2009-07-23
    The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the treatment of mycobacterial disease.
    该发明涉及一般式I、II、III、IV、V、VI、VII、VIII、IX、X的化合物,或其立体化学异构体或药学上可接受的盐,其N-氧化物形式或其前药。该化合物可用作治疗分枝杆菌病的药物。
  • 一种2,4-二氯喹啉类化合物的合成方法
    申请人:辽宁大学
    公开号:CN113121435B
    公开(公告)日:2022-08-30
    本发明公开一种2,4‑二氯喹啉类化合物的合成方法。属于有机合成技术领域。在室温下,将三光气和三苯基氧化膦混合溶于有机溶剂中,搅拌10~30min后,加入α‑取代的乙酰芳胺类化合物,将反应体系加热至90~130℃,继续搅拌反应3~6h,所得反应液经后处理得2,4‑二氯喹啉类化合物。通过本发明方法合成2,4‑二氯喹啉类化合物,步骤少,产率高,操作更加安全便捷;同时,反应中所用的三苯基氧化膦可回收循环使用,因此含磷废弃物的排放大大减少,适合工业化生产。
  • Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
    申请人:——
    公开号:US20030195194A1
    公开(公告)日:2003-10-16
    Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: 1 including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
    提供了MIF的抑制剂,对治疗各种疾病具有实用性,包括与MIF活性相关的病理条件的治疗。MIF的抑制剂具有以下结构:包括立体异构体、前药和其药用盐,其中n、R1、R2、R3、R4、X、Y和Z如本文所定义。还提供了含有MIF抑制剂的组合物,与药用载体结合,以及使用方法。
  • FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
    申请人:FUJII Nobuhiro
    公开号:US20090227561A1
    公开(公告)日:2009-09-10
    The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR 1 (R 1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R 2 is carbamoyl optionally having substituent(s); and R 3 is hydroxy optionally having substituent(s), or a salt thereof.
    本发明提供了一种具有优异的Smo抑制活性和较低毒性的化合物,该化合物作为药物产品是完全令人满意的。本发明提供了一种由下式表示的化合物: 其中,环A是5-至7-成员环,可选择地具有取代基,其中取代基可选择地与彼此结合形成环;X是O、S或NR1(R1是氢原子或具有取代基的碳氢基团);R2是氨基甲酰,可选择地具有取代基;R3是羟基,可选择地具有取代基,或其盐。
查看更多